The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature

Lin Ding, Qing-Jian Li, Kai-Yun You, Zhi-Min Jiang, He-Rui Yao, Lin Ding, Qing-Jian Li, Kai-Yun You, Zhi-Min Jiang, He-Rui Yao

Abstract

Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer.The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lung cancer and its side effects.We report 2 patients presented with advanced nonsmall-cell lung cancer, who received apatinib after failure in the first- or third-line chemotherapy. They are treated with apatinib in daily dose of 850 mg, 28 days per cycle.Favorable oncologic outcomes were achieved in the 2 cases after the treatment of apatinib. Patient I's progression-free-survival has increased to 4.6 months after palliative therapy of apatinib, whereas Patient II nearly 6 months. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of apatinib was controllable and tolerable.Apatinib may be an option for advanced nonsmall cell lung cancer after failure of chemotherapy or other targeted therapy. But that still warrants further investigation in the prospective study.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
CT shows that mass in right upper lobe (A); mass is smaller after 3 month of apatinib treatment (B). CT = computed tomography.
FIGURE 2
FIGURE 2
CT shows the mass in the lung (arrow indicate), (A) before apatinib treatment (July 2015). (B), (C) Apatinib treatment for 1 month and 3 months, respectively; local cavity can be seen. CT = computed tomography.

References

    1. Zhi XY, Zou XN, Hu M, et al. Increased lung cancer mortality rates in the Chinese population from 1973–1975 to 2004–2005: an adverse health effect from exposure to smoking. Cancer 2015; 121 suppl 17:3107–3112.
    1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27–30.
    1. Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Translational Med 2014; 2:123.
    1. Liu L, Yu H, Huang L, et al. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther 2015; 8:921–928.
    1. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007; 13:5544s–5548s.
    1. C.D., S.M., N.S. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-smallc-cell lung cancer a meta-analysis. JAMA 2004; 292:470–484.
    1. Stinchcombe TE. Targeted therapy of advanced non-small cell lung cancer:the role of bevacizumab. Biologics: Target Ther 2007; I:I85–194.2007.
    1. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3:861–865.
    1. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000; 36:601–609.
    1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542–2550.
    1. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227–1234.
    1. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102:1374–1380.
    1. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20:2768–2778.
    1. Tanigawa N, Amaya H, Matsumura M, et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997; 15:826–832.
    1. Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010; 10:529.
    1. Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer J 2014; 135:1961–1969.
    1. Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (Meeting Abstracts) 2014; 32 (15 suppl):4003.
    1. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013; 31:3219–3225.
    1. Zhang L, Shi M, Cheng H, et al. A phase II, multicenter, placebo controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol 2012; 30 (15 suppl):7548.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe